Alder gears up for migraine showdown with eptinezumab filingAlder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of Share XAlder gears up for migraine showdown with eptinezumab filinghttps://pharmaphorum.com/news/alder-gears-up-for-migraine-showdown-with-eptinezumab-filing/
European regulator restricts use of Sanofi MS drug LemtradaThe European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of Share XEuropean regulator restricts use of Sanofi MS drug Lemtradahttps://pharmaphorum.com/news/european-regulator-restricts-use-of-sanofi-ms-drug-lemtrada/
Novartis sues as Amgen tries to cancel migraine tie-upNovartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, Share XNovartis sues as Amgen tries to cancel migraine tie-uphttps://pharmaphorum.com/news/novartis-sues-as-amgen-tries-to-cancel-migraine-tie-up/
Teva’s migraine drug Ajovy approved in EuropeTeva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Share XTeva’s migraine drug Ajovy approved in Europehttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-approved-in-europe/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Celgene refiles potential MS blockbuster ozanimod with FDACelgene has filed its highly anticipated oral MS drug ozanimod with the US regulator, more than a year Share XCelgene refiles potential MS blockbuster ozanimod with FDAhttps://pharmaphorum.com/news/celgene-refiles-potential-ms-blockbuster-ozanimod-with-fda/
Karuna raises $68m to develop neurology drug KarXTKaruna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 Share XKaruna raises $68m to develop neurology drug KarXThttps://pharmaphorum.com/news/karuna-raises-68m-to-develop-neurology-drug-karxt/
Acadia faces US federal probe into Nuplazid marketingAcadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into Share XAcadia faces US federal probe into Nuplazid marketinghttps://pharmaphorum.com/news/acadia-faces-us-federal-probe-into-nuplazid-marketing/
Alexion aims for fourth rare disease use for blockbuster SolirisThe FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for Share XAlexion aims for fourth rare disease use for blockbuster Solirishttps://pharmaphorum.com/news/alexion-aims-for-fourth-rare-disease-use-for-blockbuster-soliris/
